RU95105340A - Полипептид из agelenopsis aperta, блокирующий кальциевые каналы и способ лечения заболеваний у млекопитающих - Google Patents

Полипептид из agelenopsis aperta, блокирующий кальциевые каналы и способ лечения заболеваний у млекопитающих

Info

Publication number
RU95105340A
RU95105340A RU95105340/04A RU95105340A RU95105340A RU 95105340 A RU95105340 A RU 95105340A RU 95105340/04 A RU95105340/04 A RU 95105340/04A RU 95105340 A RU95105340 A RU 95105340A RU 95105340 A RU95105340 A RU 95105340A
Authority
RU
Russia
Prior art keywords
calcium channel
polypeptide
mammalian
agelenopsis aperta
blocking calcium
Prior art date
Application number
RU95105340/04A
Other languages
English (en)
Other versions
RU2104286C1 (ru
Inventor
Филлипс Дуглас
Us]
Е.Келли Мэри
А.Саккомано Николас
А.Волькманн Роберт
Original Assignee
Пфайзер Инк. (US)
Пфайзер Инк.
Эн-Пи-Эс Фармасьютикалз
Эн-Пи-Эс Фармасьютикалз, Инк.
Инк. (US)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. (US), Пфайзер Инк., Эн-Пи-Эс Фармасьютикалз, Эн-Пи-Эс Фармасьютикалз, Инк., Инк. (US) filed Critical Пфайзер Инк. (US)
Publication of RU95105340A publication Critical patent/RU95105340A/ru
Application granted granted Critical
Publication of RU2104286C1 publication Critical patent/RU2104286C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Insects & Arthropods (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Полипептид, выделенный из яда паука Agelenopsis aperta, блокирует кальциевые каналы в клетках многих организмов и применим для блокирования кальциевых каналов в самих клетках, для лечения заболеваний, обусловленных состоянием кальциевых каналов и для борьбы с беспозвоночными - вредителями.

Claims (1)

  1. Полипептид, выделенный из яда паука Agelenopsis aperta, блокирует кальциевые каналы в клетках многих организмов и применим для блокирования кальциевых каналов в самих клетках, для лечения заболеваний, обусловленных состоянием кальциевых каналов и для борьбы с беспозвоночными - вредителями.
RU95105340A 1992-07-27 1993-06-10 Полипептид или его фармацевтически приемлемые соли RU2104286C1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91953892A 1992-07-27 1992-07-27
US07/919.538 1992-07-27
US07/919,538 1992-07-27
PCT/US1993/005392 WO1994002511A1 (en) 1992-07-27 1993-06-10 Calcium channel blocking polypeptide from agelenopsis aperta

Publications (2)

Publication Number Publication Date
RU95105340A true RU95105340A (ru) 1996-10-27
RU2104286C1 RU2104286C1 (ru) 1998-02-10

Family

ID=25442279

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95105340A RU2104286C1 (ru) 1992-07-27 1993-06-10 Полипептид или его фармацевтически приемлемые соли

Country Status (28)

Country Link
US (1) US5599559A (ru)
EP (1) EP0656905B1 (ru)
JP (1) JP2571197B2 (ru)
KR (1) KR950702577A (ru)
CN (1) CN1086824A (ru)
AT (1) ATE157672T1 (ru)
AU (1) AU662066B2 (ru)
BR (1) BR9306796A (ru)
CA (1) CA2139947C (ru)
CZ (1) CZ281539B6 (ru)
DE (1) DE69313650T2 (ru)
DK (1) DK0656905T3 (ru)
ES (1) ES2105284T3 (ru)
FI (1) FI933349A (ru)
GR (1) GR3024637T3 (ru)
HR (1) HRP931050B1 (ru)
HU (1) HU213353B (ru)
IL (1) IL106424A0 (ru)
MX (1) MX9304497A (ru)
MY (1) MY131356A (ru)
NZ (1) NZ253611A (ru)
PL (1) PL307258A1 (ru)
RU (1) RU2104286C1 (ru)
SK (1) SK10395A3 (ru)
TW (1) TW271442B (ru)
WO (1) WO1994002511A1 (ru)
YU (1) YU51593A (ru)
ZA (1) ZA935370B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407820A (en) * 1988-04-04 1995-04-18 The Salk Institute Biotechnology/Industrial Associates, Inc. Calcium channel α-2 subunit DNAs and cells expressing them
US20040018510A1 (en) 1990-11-08 2004-01-29 Merck & Co., Inc. Human calcium channel compositions and methods
US5876958A (en) * 1988-04-04 1999-03-02 Sibia Neurosciences, Inc. Assays of cells expressing human calcium channels containing α1 β subunits
US6387696B1 (en) 1988-04-04 2002-05-14 Merck & Co., Inc. Human calcium channel compositions and methods
US5846757A (en) * 1988-04-04 1998-12-08 Sibia Neurosciences, Inc. Human calcium channel α1, α2, and β subunits and assays using them
US5874236A (en) * 1988-04-04 1999-02-23 Sibia Neurosciences. Inc. DNA encoding human calcium channel α-1A, β1, β-2, and β-4 subunits, and assays using cells that express the subunits
US6096514A (en) * 1988-04-04 2000-08-01 Sibia Neurosciences, Inc. Human calcium channel compositions and methods
US6653097B1 (en) 1991-08-15 2003-11-25 Merck & Co., Inc. Human calcium channel compositions and methods
AU3548089A (en) * 1988-04-04 1989-11-03 Salk Institute Biotechnology/Industrial Associates, Inc., The Calcium channel compositions and methods
US6090623A (en) * 1993-08-11 2000-07-18 Merck & Co., Inc. Recombinant human calcium channel β4 subunits
ES2075796B1 (es) * 1993-08-17 1996-03-01 Pfizer Polipeptido de la agelenopsis aperta bloqueante de los canales de ca lcio
CA2230957A1 (en) 1995-09-29 1997-04-10 Universita'degli Studi Di Siena Regulated genes and uses thereof
WO1998007832A1 (en) 1996-08-23 1998-02-26 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
US6528630B1 (en) 1997-12-03 2003-03-04 Merck & Co., Inc. Calcium channel compositions and methods
IL140665A0 (en) * 1998-07-10 2002-02-10 Novartis Ag Antihypersensitive combination of valsartan and calcium channel blocker
US8299211B2 (en) * 2005-09-30 2012-10-30 The Board Of Trustees Of The University Of Illinois Peptides and regulation of calcium channels
CN103768469A (zh) * 2012-10-23 2014-05-07 葛继云 一种治疗妇科炎症的中药组合物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US5196204A (en) * 1986-10-20 1993-03-23 University Of Utah Research Foundation Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US5064657A (en) * 1986-10-20 1991-11-12 University Of Utah Spider toxins and methods for their use as blockers of amino acid receptor function
US5122596A (en) * 1989-09-29 1992-06-16 Pfizer Inc. Polypeptides useful as blockers of calcium channels

Also Published As

Publication number Publication date
ATE157672T1 (de) 1997-09-15
DE69313650D1 (en) 1997-10-09
GR3024637T3 (en) 1997-12-31
JP2571197B2 (ja) 1997-01-16
DK0656905T3 (da) 1997-10-20
ZA935370B (en) 1995-01-26
MY131356A (en) 2007-08-30
CA2139947A1 (en) 1994-02-03
MX9304497A (es) 1994-04-29
NZ253611A (en) 1996-09-25
HRP931050A2 (en) 1996-12-31
CN1086824A (zh) 1994-05-18
CZ281539B6 (cs) 1996-10-16
HU9302158D0 (en) 1993-11-29
IL106424A0 (en) 1993-11-15
ES2105284T3 (es) 1997-10-16
CZ9500200A3 (en) 1995-10-18
EP0656905A1 (en) 1995-06-14
YU51593A (sh) 1997-01-08
FI933349A (fi) 1994-01-28
HU213353B (en) 1997-05-28
AU4407893A (en) 1994-02-14
BR9306796A (pt) 1998-12-08
TW271442B (ru) 1996-03-01
US5599559A (en) 1997-02-04
WO1994002511A1 (en) 1994-02-03
AU662066B2 (en) 1995-08-17
HUT67467A (en) 1995-04-28
CA2139947C (en) 1998-06-30
KR950702577A (ko) 1995-07-29
DE69313650T2 (de) 1998-01-08
SK10395A3 (en) 1995-06-07
EP0656905B1 (en) 1997-09-03
RU2104286C1 (ru) 1998-02-10
JPH07504685A (ja) 1995-05-25
PL307258A1 (en) 1995-05-15
FI933349A0 (fi) 1993-07-26
HRP931050B1 (en) 1999-04-30

Similar Documents

Publication Publication Date Title
RU95105340A (ru) Полипептид из agelenopsis aperta, блокирующий кальциевые каналы и способ лечения заболеваний у млекопитающих
NO901881L (no) Fremgangsmaate for fremstilling av polyaminer og polypeptider.
YU184490A (sh) Postupak za dobijanje čistog polipeptida
RU95109941A (ru) Полипептиды theraphosidae aphonopelma, блокирующие кальциевый канал, способ лечения
RU94046023A (ru) Очищенные полипептиды из felistata hibernalis, блокирующие кальциевый канал и способы лечения на их основе
NO950293L (no) Kalsiumkanalblokkerende polypeptid fra Agelenopsis aperta
ES2075796A1 (es) Polipeptido de la agelenopsis aperta bloqueante de los canales de ca lcio